Vasopressor Administration via Peripheral IV
Disclaimer: This protocol is an educational reference intended to support — not replace — institutional policy, pharmacy and therapeutics review, and individual clinical judgment. Verify current dosing, contraindications, and local formulary/practice constraints before adopting into an EMR or using in patient care.
Overview
Vasopressors were traditionally restricted to central venous catheters (CVCs) after early case reports of extravasation-related tissue injury. Peripheral administration is now well-studied: in a 635-patient prospective study, over half of patients avoided CVC placement entirely, with a low extravasation rate (5.5%) and no case requiring surgical intervention. SSC 2026 explicitly supports peripheral vasopressor start to avoid delaying perfusion restoration while central access is obtained. The tradeoff is operational, not just clinical: safe peripheral use depends on a defined site/gauge standard, dedicated monitoring, and a clear extravasation response — not on the drug itself.
Steps
- 01
Confirm the Patient Is a Candidate
- Norepinephrine is first-line and the best-studied agent for peripheral use; phenylephrine has also been used peripherally at some centers.
- Anticipated short duration and a single vasopressor agent. Two or more vasopressors, or an anticipated prolonged course, is a peripheral contraindication (Step 5).
- Order via a defined peripheral-vasopressor order set, not an ad hoc nursing order — approval by the attending/consultant (day) or senior (night) is standard practice at sites with a mature protocol.
- 02
Site Selection and Line Requirements
Table 1. PIV requirements for vasopressor infusion
Requirement Detail Location Forearm/upper arm or antecubital — never hand, wrist, lower extremity Gauge ≥ 20 gauge, ideally ultrasound-guided placement Blood return Brisk, no resistance on flush — confirm before starting and every shift Line use Dedicated to the vasopressor only — no other medication in the same line, even if compatible Backup access A second line meeting the same criteria is recommended *Exact site/gauge rules vary by institution — the two source SOPs behind this protocol differ slightly (e.g., antecubital-acceptable vs. antecubital-excluded). The adopting site's Section Editor should set one local standard.*
- 03
Set Local Dose and Duration Thresholds
Table 2. Example thresholds from two institutional protocols reviewed for this protocol
Source Agent(s) Max dose Max duration Protocol A Norepinephrine or dopamine (single agent) Norepinephrine ≤ 12 mcg/min or dopamine ≤ 10 mcg/kg/min 24 hours Protocol B Norepinephrine or phenylephrine (single agent) Norepinephrine ≤ 15 mcg/min or phenylephrine ≤ 75 mcg/min 48 hours These numbers are not interchangeable — they reflect two different institutions' risk tolerance, not a single evidence-based cutoff. This protocol needs one locally-approved threshold before it can be built into the EMR order set.
- 04
Monitor
- Assess and document the infiltration and phlebitis scale every 1–2 hours and PRN.
- Reassess PIV function (site appearance, blood return, flush resistance) at the same interval.
- Notify the charge nurse whenever a vasopressor is infusing peripherally.
- Consider whether an arterial line can be deferred: arterial lines remain preferred for accurate/frequent BP measurement during vasopressor titration, but deferral can be considered for patients meeting the peripheral protocol, with explicit physician sign-off.
- 05
Escalate to Central Access When Any of These Apply
- A second vasopressor is needed.
- The single-agent maximum dose is reached, or the requirement is rising.
- Duration will exceed the locally approved maximum.
- Two compliant peripheral IVs cannot be established or maintained.
- Additional access is needed for fluids/other medications.
- The infusion requires a hypertonic, high/low-pH, or concentrated electrolyte solution not appropriate for peripheral use.
- During acute resuscitation, CVC placement can be deferred up to ~2 hours to avoid delaying reversal of shock; if no vascular access can be established within 5 minutes, consider intraosseous access.
- 06
Respond Immediately to Extravasation
- Any sign of extravasation (pain, swelling, blanching, cord formation) → stop the infusion, notify the provider immediately, and follow the local extravasation/infiltration management protocol.
- Stock the rescue agents needed for a fast response before go-live — phentolamine and nitroglycerin paste were both cited as unit stock items in the source protocols reviewed for this protocol.
- Complete an adverse-event report for any site or insertion complication, peripheral or central.
Algorithm
Scroll sideways to see the full algorithm.
EMR Order Set
- Peripheral vasopressor order set entry, naming the approving consultant/senior, with the agent and locally-approved max dose built in as order limits (not free text).
- Arterial-line-deferral order, separate and explicit, when applicable.
- Vein assessment scale documentation at insertion.
- Infiltration/Phlebitis scale documentation, structured field, every 1–2 hours and PRN.
- Task reminder every 12 hours for consultant/senior re-review of continued peripheral use (auto-generated, not memory-dependent).
- Extravasation protocol activation order, one click from the vasopressor MAR entry.
- Standard-concentration verification for peripheral-appropriate dosing.
- Dose-limit alert if ordered/titrated dose approaches or exceeds the local peripheral maximum.
Build notes — the dose ceiling and duration ceiling should hard-stop or hard-alert in the pump/MAR integration, not rely on nursing recognition; the 12-hour (or locally chosen) re-review task should be genuinely recurring, not a one-time checkbox.
Adoption Notes
- This protocol cannot go live without a local P&T/nursing/pharmacy decision on the exact agent list, dose ceiling, and duration ceiling (Step 3) — that decision, not the clinical concept, is the actual rollout blocker.
- Confirm phentolamine and nitroglycerin paste are stocked on the unit before go-live.
- Champion: pairs well with a vascular access/PIVAT nursing champion plus a pharmacy co-sign, given the dosing and monitoring load sits mostly with nursing and pharmacy.
- Stage rollout: pilot with norepinephrine only before adding a second agent to the approved list.
Success Metrics & Monitoring
CVC-days avoided (or CVC placement rate before/after protocol implementation, mirroring the Yerke et al. study design), extravasation rate and severity, rate of protocol-compliant site/gauge documentation, and time from vasopressor decision to infusion start. Track via nursing flowsheet data and adverse-event reporting; review monthly during rollout.
Suggested Reading
- [1]
Yerke JR, Mireles-Cabodevila E, Chen AY, et al. Peripheral Administration of Norepinephrine: A Prospective Observational Study. *Chest*. 2024;165(2):348–355. doi:10.1016/j.chest.2023.08.019. The largest prospective implementation study to date (635 patients); over half avoided CVC placement, extravasation rate 5.5% with no case requiring surgical intervention — the primary evidence this protocol is built on.
- [2]
Munroe ES. A Case for the Evidence-Based Use of Peripheral Vasopressors. *Chest*. 2024;165(2):238–239. Editorial accompanying Yerke et al. above; argues norepinephrine should remain first-line regardless of route, and flags PIV-monitoring frequency as still unstandardized — reflected in this protocol's Step 4.
- [3]
Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. *J Hosp Med*. 2015. doi:10.1002/jhm.2394. One of the two large prospective studies establishing peripheral vasopressor safety with 2-hourly PIV monitoring.
- [4]
Parienti JJ, Mongardon N, Mégarbane B, et al. Intravascular complications of central venous catheterization by insertion site. *N Engl J Med*. 2015;373(13):1220–1229. Quantifies the CVC complication rates (pneumothorax, CRBSI, DVT) that peripheral administration aims to avoid.
- [5]
Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. *Crit Care Med*. 2026;54(4):725–812. doi:10.1097/CCM.0000000000007075. Supports peripheral norepinephrine start under a defined safety protocol rather than delaying vasopressors for central access — see the companion [Sepsis and Septic Shock](sepsis-septic-shock.md) protocol.
Revision History
| Version | Date | Editor | Summary |
|---|---|---|---|
| 0.1 | 2026-07-19 | FunctionalHealth editorial team | Initial version grounded in two institutional SOPs and current literature from the local source folder |
Disclaimer: This protocol is an educational reference intended to support — not replace — institutional policy, pharmacy and therapeutics review, and individual clinical judgment. Verify current dosing, contraindications, and local formulary/practice constraints before adopting into an EMR or using in patient care.